Prognostic value of MRD in Ph^–adult ALL. (A) Probability of OS for patients in the standard-risk and high-risk groups according to molecular response (MR) status (leukemia-associated IG/TR rearrangements detected by RT-qPCR) after induction or early consolidation chemotherapy (week 16) excluding SCT in CR1.²⁰  Results of the GMALL 06/99 and 07/03 trials. Complete molecular remission (MolCR) is defined as MRD negativity with an assay sensitivity of at least 10^–4. Molecular failure (MolFail) is defined as quantifiable MRD positivity ≥10^–4. (B) OS according to different molecular levels of postinduction MRD (detected by IG/TR RT-qPCR). Results of the NILG ALL 09/00 trial. Complete molecular remission (CMR) is defined as MRD negativity at weeks 10, 16, and 22. MR is defined as MRD <10^–4 at week 10 and/or week 16 and/or week 22. Molecular resistance type 1 (MR1) is defined as measurable MRD ≥10^–4 and <10^–3. MR2 is defined as measurable MRD ≥10^–3. Panel B adapted from Bassan et al³¹  with permission. (C) Effect of SCT on OS. Results of the GRAALL-2003/2005 trials. Simon-Makuch plots of SCT time-dependent analysis of OS according to molecular MRD response (≥10^–3or <10^–3) and type of postremission therapy (SCT vs no SCT) in high-risk ALL. MRD was detected by IG/TR-based RT-qPCR. Panel C adapted from Dhédin et al.²⁴  (D) OS for patients with relapsed or refractory BCP-ALL receiving salvage immunotherapy (inotuzumab ozogamicin or blinatumomab) by MRD response (MRD positive or MRD negative by 6-color MFC) and salvage status (Salvage 1 [S1] vs Salvage 2 [S2]). Retrospective analysis at MD Anderson Cancer Center. Includes data from 4 Ph⁺ patients. Panel D adapted from Jabbour et al⁴⁶  with permission.